FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

* Diagnosis of B-cell CLL
* Relapsed, fludarabine-sensitive (duration of response \> 6 months as assessed by prior treating physician) or fludarabine-naive patients
* Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling of peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms.
* Prestudy WHO Performance Status \</= 2.
* Signed, written Institutional Review Board (IRB)approved informed consent.
* Men and women of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment.
* Acceptable liver function: Bilirubin \</= 2.0 mg/dL (26 umol/L), AST (SGOT) and/or ALT (SGPT) \</= 2 times upper limit of normal.
* Acceptable hematologic status: Platelet count \>/= 50 x 10\^9/L., absolute neutrophil count (ANC) \>/= 1 x 10\^9/L.
* Acceptable renal function: Serum creatinine \</= 2.0 mg/dL

Exclusion Criteria:

* Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1.
* Known infection with HIV, hepatitis B, or hepatitis C
* Transformation to aggressive B-cell malignancy (e.g., large B-cell lymphoma, Richter's Syndrome, or prolymphocyte leukemia \[PLL\]).
* Patients with secondary malignancy requiring active treatment (except hormonal therapy).
* Active uncontrolled bacterial, viral, or fungal infections.
* New York Heart Association Class II-IV cardiac disease or myocardial infarction within the past 6 months prior to Study Day 1.
* Pregnant or currently breast-feeding.
* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study.
* Blood pressure of \> 150/100 mmHg
* Unstable angina
* History of stroke within 6 months
* Clinically significant peripheral vascular disease
* Evidence of bleeding diathesis or coagulopathy
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study.
* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 1.
* Urine protein:creatinine ratio \>/= 1.0 at screening.
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1.
* Serious, non-healing wound, ulcer, or bone fracture.